Subscribe
shutterstock_1899198520_t_schneider
T. Schneider / Shutterstock.com
9 November 2021MedtechAlex Baldwin

Qiagen and BD settle PCR lawsuit for £53m

Qiagen will pay Becton, Dickinson (BD) $53 million to settle an ongoing patent infringement lawsuit over polymerase chain reaction (PCR) diagnostics patents.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Qiagen seeks judgment in COVID-19 wastewater testing suit
7 April 2022   Qiagen has asked a Delaware court to issue a declaratory judgment that its method for testing for COVID-19 in wastewater does not infringe Bio-Rad’s patents.
Americas
Jury rules Qiagen infringed two gene patents
31 August 2021   A US District Court for the District of Delaware jury found that German genetics company Qiagen willfully infringed two patents owned by ArcherDX and Massachusetts General Hospital.
Americas
Oxford Immunotec settles with Qiagen, signs $27.5m licence
18 December 2017   UK-based diagnostics company Oxford Immunotec has settled a patent infringement dispute with Qiagen, a provider of sample and assay technologies for molecular diagnostics.


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

More on this story

Big Pharma
Qiagen seeks judgment in COVID-19 wastewater testing suit
7 April 2022   Qiagen has asked a Delaware court to issue a declaratory judgment that its method for testing for COVID-19 in wastewater does not infringe Bio-Rad’s patents.
Americas
Jury rules Qiagen infringed two gene patents
31 August 2021   A US District Court for the District of Delaware jury found that German genetics company Qiagen willfully infringed two patents owned by ArcherDX and Massachusetts General Hospital.
Americas
Oxford Immunotec settles with Qiagen, signs $27.5m licence
18 December 2017   UK-based diagnostics company Oxford Immunotec has settled a patent infringement dispute with Qiagen, a provider of sample and assay technologies for molecular diagnostics.

More on this story

Big Pharma
Qiagen seeks judgment in COVID-19 wastewater testing suit
7 April 2022   Qiagen has asked a Delaware court to issue a declaratory judgment that its method for testing for COVID-19 in wastewater does not infringe Bio-Rad’s patents.
Americas
Jury rules Qiagen infringed two gene patents
31 August 2021   A US District Court for the District of Delaware jury found that German genetics company Qiagen willfully infringed two patents owned by ArcherDX and Massachusetts General Hospital.
Americas
Oxford Immunotec settles with Qiagen, signs $27.5m licence
18 December 2017   UK-based diagnostics company Oxford Immunotec has settled a patent infringement dispute with Qiagen, a provider of sample and assay technologies for molecular diagnostics.

More features

Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
ResMed voids sleep apnoea tech patent at PTAB